Clene Inc. (NASDAQ:CLNN – Get Free Report) has been given a consensus rating of “Moderate Buy” by the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $34.00.
Several research analysts have weighed in on CLNN shares. Weiss Ratings raised Clene from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, November 11th. HC Wainwright reiterated a “buy” rating on shares of Clene in a research note on Monday, October 19th. Finally, Wall Street Zen raised Clene from a “sell” rating to a “hold” rating in a report on Saturday, November 7th.
Check Out Our Latest Research Report on CLNN
Institutional Trading of Clene
Clene Price Performance
Shares of NASDAQ CLNN opened at $3.52 on Thursday. The business has a 50-day moving average of $3.87 and a 200-day moving average of $5.09. The stock has a market capitalization of $50.69 million, a price-to-earnings ratio of -1.35 and a beta of 1.04. Clene has a fifty-two week low of $3.02 and a fifty-two week high of $10.84.
Clene (NASDAQ:CLNN – Get Free Report) last released its earnings results on Wednesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.50. The company had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.07 million. On average, sell-side analysts expect that Clene will post -1.05 EPS for the current year.
About Clene
Clene Inc. is a clinical-stage biopharmaceutical company developing nanotherapeutic treatments for neurodegenerative diseases. Founded in 2013 and based in Salt Lake City, Utah, the company focuses on research and development rather than marketed medicines. Its lead investigational candidate, CNM-Au8, is a suspension of gold nanocrystals designed to support cellular energy production and protect nerve cells. Clene has studied CNM-Au8 in clinical programs for conditions including amyotrophic lateral sclerosis (ALS) and multiple sclerosis.
See Also
- Five stocks we like better than Clene
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Clene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clene and related companies with MarketBeat.com's FREE daily email newsletter.
